Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buloxibutid for Endothelial Dysfunction in T2DM
NCT05831644Phase 1Completed
- Sponsor
- Vicore Pharma
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of buloxibutid in endothelial dysfunction (2 arms), sponsored by Vicore Pharma. Primary endpoint: Pharmacodynamic Effect at 15 days. Started Mar 2023; status: completed.
02
Drugs
buloxibutid
03
Conditions
endothelial dysfunction
Beyond the preview
Go deeper on NCT05831644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05831644.